Lates News

Olin Biology announced that it has recently noticed some untrue comments on certain online platforms regarding the Phase III clinical trial data of the company's recombinant Staphylococcus aureus vaccine. The 73.25% protection efficacy data disclosed by the company from the Phase III clinical trial results was calculated by an independent third-party statistical team, and the company truthfully made information disclosure based on the report issued by this independent third party. Upon verification, it was found that the data used in the online circulated "Recombinant Staphylococcus aureus Vaccine Phase III Clinical Data Audit Report," such as the number of confirmed cases, total number of subjects, and the conclusions, are inconsistent with the actual situation of the company's clinical trials.